help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by NAGASE, T.
Right arrow Articles by SHIMIZU, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by NAGASE, T.
Right arrow Articles by SHIMIZU, T.

Am. J. Respir. Crit. Care Med., Volume 156, Number 5, November 1997, 1621-1627

Airway Responsiveness in Transgenic Mice Overexpressing Platelet-activating Factor Receptor
Roles of Thromboxanes and Leukotrienes

TAKAHIDE NAGASE, SATOSHI ISHII, HIROFUMI KATAYAMA, YOSHINOSUKE FUKUCHI, YASUYOSHI OUCHI, and TAKAO SHIMIZU

Department of Geriatrics, Department of Biochemistry, Faculty of Medicine, University of Tokyo, Tokyo, Japan

Platelet-activating factor (PAF) is a potent proinflammatory compound potentially involved in the pathogenesis of inflammatory disorders, including bronchial asthma. To elucidate the pathophysiologic roles of PAF in bronchial asthma, we studied airway responsiveness in transgenic mice overexpressing PAF receptor. In the transgenic mice, PAF-induced airway smooth muscle contraction was demonstrated by physiologic and morphometric analyses, whereas there was no significant response in the littermate control group. The PAF-elicited bronchoconstriction in the transgenic mice was significantly reduced not only by a PAF receptor antagonist (WEB-2086) but also by a thromboxane synthesis inhibitor (indomethacin or ozagrel), an inhibitor of 5-lipoxygenase-activating protein (MK-886), or a cysteinyl leukotriene (LT) antagonist (pranlukast). LTB4 receptor antagonist (ONO-4057), however, had no effect on the PAF-induced responses. The transgenic mice showed a bronchial hyperreactivity to methacholine challenge, which was also inhibited by pretreatment with either thromboxane synthesis inhibitor or cysteinyl LT antagonist. These observations suggest that both thromboxane A2 and cysteinyl LTs (LTC4, LTD4, and LTE4) are involved in the bronchial responses to PAF or cholinergic stimulus in mice. The transgenic mice overexpressing PAF receptor may provide an appropriate model to study various PAF-related lung diseases, including bronchial asthma.




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
A. R. Leff and N. M. Munoz
Future Treatment to Lessen Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 659 - 666.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
A. J. Casillan, N. C. Gonzalez, J. S. Johnson, D. R. S. Steiner, and J. G. Wood
Mesenteric microvascular inflammatory responses to systemic hypoxia are mediated by PAF and LTB4
J Appl Physiol, June 1, 2003; 94(6): 2313 - 2322.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. Nagase, N. Uozumi, T. Aoki-Nagase, K. Terawaki, S. Ishii, T. Tomita, H. Yamamoto, K. Hashizume, Y. Ouchi, and T. Shimizu
A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice
Am J Physiol Lung Cell Mol Physiol, May 1, 2003; 284(5): L720 - L726.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. Aoki-Nagase, T. Nagase, Y. Oh-hashi, T. Shindo, Y. Kurihara, Y. Yamaguchi, H. Yamamoto, T. Tomita, E. Ohga, R. Nagai, et al.
Attenuation of antigen-induced airway hyperresponsiveness in CGRP-deficient mice
Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L963 - L970.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. R. Silva, E. F. de Assis, L. F. C. Caiado, G. K. Marathe, M. T. Bozza, T. M. McIntyre, G. A. Zimmerman, S. M. Prescott, P. T. Bozza, and H. C. Castro-Faria-Neto
Monocyte Chemoattractant Protein-1 and 5-Lipoxygenase Products Recruit Leukocytes in Response to Platelet-Activating Factor-Like Lipids in Oxidized Low-Density Lipoprotein
J. Immunol., April 15, 2002; 168(8): 4112 - 4120.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. NAGASE, S. ISHII, H. SHINDOU, Y. OUCHI, and T. SHIMIZU
Airway Hyperresponsiveness in Transgenic Mice Overexpressing Platelet Activating Factor Receptor Is Mediated by an Atropine-Sensitive Pathway
Am. J. Respir. Crit. Care Med., January 15, 2002; 165(2): 200 - 205.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. R. Henderson Jr., J. Lu, K. M. Poole, G. N. Dietsch, and E. Y. Chi
Recombinant Human Platelet-Activating Factor- Acetylhydrolase Inhibits Airway Inflammation and Hyperreactivity in Mouse Asthma Model
J. Immunol., March 15, 2000; 164(6): 3360 - 3367.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
T. Nagase, H. Kurihara, Y. Kurihara, T. Aoki-Nagase, R. Nagai, and Y. Ouchi
Disruption of ET-1 gene enhances pulmonary responses to methacholine via functional mechanism in knockout mice
J Appl Physiol, December 1, 1999; 87(6): 2020 - 2024.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. J. Barnes, K. F. Chung, and C. P. Page
Inflammatory Mediators of Asthma: An Update
Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society 		  ATS Sleep Tracings Quiz